Free Trial
→ U.S. Army Advances 75-Year Rare Earth Deal With Nasdaq Firm (From The Tomorrow Investor) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$159.91
+1.2%		$234.93
$156.00
▼
$479.79
$21.38B0.281.54 million shs2.17 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$55.20
+0.5%		$37.55
$23.62
▼
$59.97
$34.45B0.812.49 million shs1.91 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$8.26
+3.9%		$8.71
$1.95
▼
$12.43
$8.76B0.0220.02 million shs3.76 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$36.29
+1.1%		$36.64
$19.32
▼
$42.50
$26.19B1.16.43 million shs3.71 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-4.24%-30.60%-28.09%-27.85%-65.35%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
-3.75%+22.89%+58.04%+89.25%+91.96%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-4.10%+1.79%-22.67%+14.39%+231.25%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-2.76%-0.44%+0.48%+3.76%+79.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$159.91
+1.2%		$234.93
$156.00
▼
$479.79
$21.38B0.281.54 million shs2.17 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$55.20
+0.5%		$37.55
$23.62
▼
$59.97
$34.45B0.812.49 million shs1.91 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$8.26
+3.9%		$8.71
$1.95
▼
$12.43
$8.76B0.0220.02 million shs3.76 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$36.29
+1.1%		$36.64
$19.32
▼
$42.50
$26.19B1.16.43 million shs3.71 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-4.24%-30.60%-28.09%-27.85%-65.35%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
-3.75%+22.89%+58.04%+89.25%+91.96%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-4.10%+1.79%-22.67%+14.39%+231.25%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-2.76%-0.44%+0.48%+3.76%+79.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.65
Moderate Buy$305.8691.27% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.92
Moderate Buy$53.61-2.88% Downside
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.71
Moderate Buy$16.0093.61% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.79
Moderate Buy$46.5528.25% Upside

Current Analyst Ratings Breakdown

Latest IBRX, GMAB, ALNY, and ROIV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/2/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$450.00 ➝ $380.00
11/2/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$429.00 ➝ $323.00
11/2/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold$315.00 ➝ $225.00
10/30/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$550.00 ➝ $329.00
10/30/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform$290.00
10/30/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$460.00 ➝ $287.00
10/30/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Outperform$420.00 ➝ $315.00
10/30/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$425.00 ➝ $375.00
10/30/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$350.00 ➝ $320.00
10/30/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$482.00 ➝ $354.00
10/30/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetEqual Weight$42.00 ➝ $57.00
(Data available from 11/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$3.71B5.76$1.92 per share83.11$5.97 per share26.79
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$4.13B8.34$1.55 per share35.59$9.10 per share6.07
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$165.79M52.83N/AN/A($0.51) per share-16.20
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$7.53M3,480.52N/AN/A$7.35 per share4.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$19.268.3017.71N/A15.26%84.93%14.30%N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.2743.4732.472.4719.08%14.89%7.73%11/5/2026 (Estimated)
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$351.40M-$0.97N/AN/AN/A-598.55%N/A-51.65%11/3/2026 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.53N/AN/AN/A-3,534.96%-22.94%-21.53%11/9/2026 (Estimated)

Latest IBRX, GMAB, ALNY, and ROIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q2 2027
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.3666N/AN/AN/A$4.15 millionN/A
11/5/2026Q3 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.36N/AN/AN/A$1.20 billionN/A
11/3/2026Q3 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.07N/AN/AN/A$59.23 millionN/A
10/29/2026Q3 2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$1.66$16.26+$14.60$15.72$1.43 billion$1.46 billion
8/7/2026Q1 2027
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.2996-$0.26+$0.0396-$0.26$2.06 million$1.44 million
8/6/2026Q2 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.37$0.54+$0.17$0.4910$1.12 billion$1.16 billion
8/4/2026Q2 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.08-$0.22-$0.14-$0.22$49.70 million$51.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.75
3.05
2.99
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.81
2.46
2.44
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
5.72
5.70
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
16.72
16.72

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.86%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
66.10%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
8.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.81 million132.79 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029624.06 million614.45 millionOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
6911.06 billion359.28 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
721722.32 million658.76 millionOptionable

Recent News About These Companies

Roivant Sciences Insider Sold Shares Worth $7,318,000, According to a Recent SEC Filing
November 3 at 3:38 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/roivant-sciences-insider-sold-shares-085316812.html
Roivant's Venker sells 14.3% of shares held under a trading plan (NASDAQ: ROIV)
November 3 at 3:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31175144
Immunovant Heads Into Q3 With Flat Losses Expected And A 23% Slide To Explain
November 2 at 5:37 PM  |  finviz.comF
Roivant Sciences (ROIV) Set to Announce Quarterly Earnings on Monday
November 2 at 8:55 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-roivant-sciences-roiv-set-to-announce-quarterly-earnings-on-monday-2026-11-02/
201,261 Shares of Roivant Sciences Ltd. $ROIV Acquired by Asset Management One Co. Ltd.
November 2 at 3:51 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-201261-shares-of-roivant-sciences-ltd-roiv-acquired-by-asset-management-one-co-ltd-2026-11-02/
Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Has Consensus Price Target of $46.55 According to Brokerages
November 1 at 3:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-roivant-sciences-ltd-nasdaq-roiv-stock-has-consensus-price-target-of-4655-according-to-brokerages-2026-11-01/
Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 200,000 Shares
October 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-roivant-sciences-nasdaq-roiv-stock-insider-eric-venker-sells-200000-shares-2026-10-30/
Roivant Sciences (NASDAQ:ROIV) Stock Price Expected to Rise, Citigroup Analyst Says
October 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31166894
Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift
October 29, 2026  |  marketscreener.comM
Roivant Sciences (NASDAQ:ROIV) Share Price Crosses Above 50-Day Moving Average - Here's What Happened
October 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-roivant-sciences-nasdaq-roiv-share-price-crosses-above-50-day-moving-average-heres-what-happened-2026-10-29/
Roivant Sciences (NASDAQ:ROIV) Stock Gets Price Target Increase from Citigroup
October 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-roivant-sciences-nasdaq-roiv-stock-gets-price-target-increase-from-citigroup-2026-10-28/
Roivant Sciences (NASDAQ:ROIV) & Verastem (NASDAQ:VSTM) Head-To-Head Survey
October 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31161869
Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis - Slideshow
October 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4957274-roivant-sciences-ltd-roiv-discusses-phase-3-results-for-brepocitinib-in-non-infectious
Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials
October 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/roivant-soars-8-brepocitinib-delivers-172526279.html
Analysts Conflicted on These Healthcare Names: Roivant Sciences (ROIV) and 4D Molecular Therapeutics (FDMT)
October 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8359027/analysts-conflicted-on-these-healthcare-names-roivant-sciences-roiv-and-4d-molecular-therapeutics-fdmt/
Roivant Sciences (NASDAQ:ROIV) CEO Sells $7,022,000.00 in Stock
October 23, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-roiv-insider-buying-and-selling-2026-10-23/
Roivant Sciences Ltd. $ROIV Shares Newly Purchased by Sumitomo Mitsui DS Asset Management Company Ltd
October 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-roivant-sciences-ltd-roiv-shares-newly-purchased-by-sumitomo-mitsui-ds-asset-management-company-ltd-2026-10-23/
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Company Stock
October 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-roivant-sciences-nasdaq-roiv-ceo-eric-venker-sells-200000-shares-of-company-stock-2026-10-22/
Roivant’s TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease
October 22, 2026  |  biospace.comB
Roivant Sciences Ltd. announces positive results in CLARITY-1 and CLARITY-2 phase 3 trials for brepocitinib
October 22, 2026  |  msn.comhttps://www.msn.com/en-us/science/general/roivant-sciences-ltd-announces-positive-results-in-clarity-1-and-clarity-2-phase-3-trials-for-brepocitinib/ar-AA2fLCqO
Stocks making the biggest moves midday: SpaceX, Meta Platforms, Super Micro Computer, Roivant Sciences & more
October 21, 2026  |  cnbc.comhttps://www.cnbc.com/2026/10/21/stocks-making-the-biggest-moves-midday-spcx-meta-smci-roiv.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$159.91 +1.91 (+1.21%)
As of 02:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$55.20 +0.28 (+0.51%)
As of 02:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$8.26 +0.31 (+3.95%)
As of 02:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$36.29 +0.40 (+1.12%)
As of 02:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas